New research suggests that adults who receive the shingles vaccine may be less likely to develop dementia. A neurologist explains the connection between shingles, inflammation and brain health.
Lecanemab and donanemab, antibody treatments administered intravenously, are the latest therapies clinically proven to slow the rate of cognitive decline.